AdHer-2/neu transduced dendritic cells(Ontario Clinical Oncology Group)

Background:
- Human epidermal growth factor receptor 2 (HER2, also known as c-erbB2 or neu)/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon, prostate and non-small cell lung. Tumors that overexpress HER2 can be associated with a more aggressive cancer, higher recurrence rates, and reduced survival rates. Researchers are testing a therapeutic cancer vaccine designed to stimulate the immune system to recognize HER2. The vaccine, called adenoviral transduced autologous human epidermal growth factor receptor (AdHER)/neu dendritic cell vaccine, is custom-made using an individual's own immune cells. These cells will be collected and used to produce the vaccine.
Objectives:
- To test the safety and effectiveness of AdHER2 vaccination.
Eligibility:
- Individuals at least 18 years of age who have HER2-expressing tumors.
Design:
Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed.
Participants will have an apheresis procedure to collect immune cells to create the vaccine.
Participants will receive five doses of the vaccine at study Weeks 0, 4, 8, 16 and 24.
Participants will be monitored with physical exams, frequent blood tests and imaging studies.